Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC)
Related Posts
Huang SY, Murray M, Rubio A, Okoro N, Sedrak MS, McCloskey SA, Jackson N, Teshome M, Kapoor NS. Impact of Screening Mammography on Breast Cancer[...]
Gower A, Win S, Ganguly R, Johnson M, Velez MA, Cummings AL, Lisberg A, Garon EB, Di Carlo B. Identification of Targetable EGFR Mutations in Ovarian Cancer.[...]
Chang K, Delavan HM, Yip E, Kasap C, Zhu J, Lodha R, Liao SY, Berman SC, Carretero-Gonzalez A, Basar M, Gokturk Ozcan G, Teo MY,[...]